The Chemours Company (NYSE: CC) filed its Form 10-Q for the quarterly period ended June 30, 2026, reporting a net loss attributable to Chemours of $274 million for the second quarter and $303 million for the first half of the year.

Key Highlights

  • Q2 net sales: $1,591 million for the three months ended June 30, 2026, compared to $1,615 million in the same period of 2025, according to the filing.
  • Net loss attributable to Chemours: $274 million in Q2 2026, versus a net loss of $380 million in Q2 2025.
  • Basic and diluted loss per share: $(1.81) for Q2 2026, compared to $(2.53) in Q2 2025.
  • Total assets: $7,150 million at June 30, 2026, down from $7,382 million at December 31, 2025.
  • Long-term debt, net: $3,838 million at June 30, 2026, reduced from $4,099 million at December 31, 2025.
  • Shares outstanding: 150,498,995 shares of common stock as of July 30, 2026, per the filing.
  • Total stockholders' equity attributable to Chemours: $(49) million at June 30, 2026, compared to $250 million at December 31, 2025.

Chemours Q2 2026 Financial Results: Revenue, Losses, and Balance Sheet Shifts

According to the filing, Chemours reported net sales of $1,591 million for the three months ended June 30, 2026, a decrease from $1,615 million in the comparable prior-year period. Gross profit for the quarter was $286 million, up slightly from $278 million in Q2 2025. However, total other operating expenses rose to $499 million from $470 million a year earlier, driven in part by selling, general, and administrative expense increasing to $469 million from $424 million. The company also recorded a loss on extinguishment of debt of $2 million in Q2 2026, and other income, net of $273 million.

The filing disclosed a provision for income taxes of $273 million in Q2 2026, contributing to a net loss of $274 million for the quarter. For the six months ended June 30, 2026, net sales totaled $2,972 million and the net loss attributable to Chemours was $303 million, with basic and diluted loss per share of $(2.01). Restructuring, asset-related, and other charges for the first half of 2026 were reported at $16 million, compared to $51 million in the first half of 2025.

On the balance sheet, the filing reported cash and cash equivalents of $671 million at June 30, 2026, essentially flat with $670 million at year-end 2025. Inventories declined to $1,452 million from $1,569 million at December 31, 2025. Total liabilities increased to $7,198 million from $7,131 million over the same period, with long-term environmental remediation rising to $671 million from $530 million. Total equity turned negative at $(48) million as of June 30, 2026, compared to positive $251 million at December 31, 2025, according to the filing.

What Was Disclosed

Chemours filed its quarterly report covering the period ended June 30, 2026, disclosing Q2 net sales of $1,591 million, a net loss attributable to Chemours of $274 million, total assets of $7,150 million, and total equity of $(48) million at quarter end.